Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus ...Middle East

Medscape - News
Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib in a new trial shows that efficacy extends to cutaneous lupus. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus )

Apple Storegoogle play

Also on site :

Most viewed in News